About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- Breast cancer: biennial mammography age 40-74 for average-risk women (USPSTF 2024)
- Cervical cancer: cytology q3y age 21-29; age 30-65 choose cytology q3y, primary hrHPV q5y, or cotesting q5y
- Colorectal cancer: screen all average-risk adults age 45-75; individualize age 76-85; stop after 85
- Lung cancer: annual low-dose CT age 50-80 with >=20 pack-years and current smoking or quit <15 years ago
- Prostate cancer: PSA screening is shared decision-making age 55-69; do not routinely screen age >=70
Overview
Cancer screening is a core USMLE Step 2 CK preventive medicine domain. The exam usually tests whether screening is indicated, which modality is preferred, when to start or stop, and when screening becomes diagnostic evaluation. For average-risk adults, Step 2 CK generally follows USPSTF recommendations because they are age-based, evidence-graded, and commonly used in US primary care. Higher-risk patients, including those with hereditary syndromes, strong family history, prior cancer, inflammatory bowel disease, immunocompromise, or prior high-grade dysplasia, often need earlier or more intensive screening and are not covered by the routine average-risk algorithm.
Epidemiology
Cancer remains the second leading cause of death in the United States after cardiovascular disease. Screening reduces mortality when it detects clinically important disease early enough for effective treatment, as with cervical, colorectal, breast, and lung cancer in selected high-risk smokers. Harms include false positives, overdiagnosis, procedure complications, anxiety, radiation exposure, and downstream biopsies. Screening decisions therefore depend on age, life expectancy, baseline risk, test performance, and whether abnormal results can be followed by effective treatment.
Screening Criteria and High-Yield Eligibility
Symptoms
Average-risk adult with no symptoms: use age-based screening intervals rather than diagnostic workup
Breast: women age 40-74 should receive mammography every 2 years; dense breasts alone do not automatically mandate ultrasound or MRI under USPSTF guidance
Cervical: start at age 21 regardless of age at sexual debut; do not screen younger than 21
Colorectal: start at age 45 for average-risk adults using stool-based testing or direct visualization
Lung: annual LDCT only if age 50-80 plus >=20 pack-year history plus current smoking or quit within 15 years
Prostate: PSA is not routine population screening; age 55-69 requires informed shared decision-making
Any alarm symptom such as rectal bleeding, breast mass, postcoital bleeding, hemoptysis, or weight loss converts screening into diagnostic evaluation
Signs
Screening applies to asymptomatic patients; a palpable mass, abnormal bleeding, or visible lesion requires diagnostic testing
Limited life expectancy or inability/unwillingness to undergo definitive treatment usually argues against screening
Prior total hysterectomy with cervix removed for benign disease: no cervical cancer screening
History of CIN2/3, cervical cancer, DES exposure, or immunocompromise: routine cervical screening rules do not apply
Family history of colorectal cancer in a first-degree relative may require colonoscopy earlier than age 45
Screening Tests and Interpretation
First-line
Breast cancer — mammographyUSPSTF: biennial mammography age 40-74 for average-risk women. Abnormal screening mammogram is followed by diagnostic mammography, targeted ultrasound, and biopsy when indicated
Cervical cancer — cytology and/or hrHPV testingAge 21-29: cytology every 3 years. Age 30-65: cytology every 3 years, primary hrHPV every 5 years, or cotesting every 5 years. Stop after 65 if adequate prior negative screening and no high-risk history
Colorectal cancer — stool testing or visualizationOptions include annual FIT, stool DNA-FIT every 1-3 years, CT colonography every 5 years, flexible sigmoidoscopy every 5 years, flexible sigmoidoscopy every 10 years plus annual FIT, or colonoscopy every 10 years
Second-line
Lung cancer — low-dose CTAnnual LDCT age 50-80 with >=20 pack-years and current smoking or quit within 15 years. Stop once quit >=15 years or if comorbidity substantially limits curative lung surgery
Prostate cancer — PSAShared decision-making age 55-69. Do not routinely screen age >=70. Elevated PSA is not diagnostic of cancer and may lead to MRI, repeat PSA, or biopsy depending on risk
Risk assessmentFamily history, hereditary syndrome, immunocompromise, prior dysplasia, and prior radiation can override average-risk screening intervals
Specialist
Genetic counselingConsider for BRCA-associated breast/ovarian cancer risk, Lynch syndrome, familial adenomatous polyposis, or multiple relatives with early-onset cancers
Diagnostic evaluationSymptoms such as hematochezia, palpable breast mass, abnormal uterine bleeding, or hemoptysis require diagnostic testing even if the patient is younger than screening age
Screening Recommendations
USPSTF Cancer Screening Recommendations; ACS selected cancer screening guidance1
Breast cancer
- Average-risk women age 40-74: mammography every 2 years
- Age >=75: evidence insufficient under USPSTF; individualize based on health status, preferences, and life expectancy
- High-risk patients (BRCA mutation, strong family history, prior chest radiation): earlier screening, breast MRI, and genetics referral may be appropriate
- Do not order tumor markers for breast cancer screening
2
Cervical cancer
- Age <21: no screening, regardless of sexual activity
- Age 21-29: Pap/cytology every 3 years
- Age 30-65: cytology q3y OR primary hrHPV q5y OR cotesting q5y
- Age >65: stop if adequate prior negative screening and no CIN2+ history in the past 25 years
- After total hysterectomy for benign disease with cervix removed: no screening
3
Colorectal cancer
- Age 45-75: screen all average-risk adults
- Age 76-85: individualize based on prior screening, comorbidity, and life expectancy
- Age >85: do not screen
- Positive stool-based test must be followed by colonoscopy; the stool test itself does not complete evaluation
- Colonoscopy interval is every 10 years if normal and average risk
4
Lung and prostate cancer
- Lung: annual LDCT for eligible adults age 50-80 with >=20 pack-years and current smoking or quit <15 years ago
- Do not use chest X-ray or sputum cytology for lung cancer screening
- Prostate: age 55-69 shared decision-making for PSA screening
- Do not routinely screen for prostate cancer age >=70
Complications
- False positives: Lead to anxiety, additional imaging, biopsies, and procedural risk
- False negatives: May falsely reassure patients and delay diagnosis if symptoms develop
- Overdiagnosis: Detection of indolent disease that would never have caused symptoms or death, especially prostate and some breast cancers
- Procedure complications: Colonoscopy can cause bleeding or perforation; biopsy can cause bleeding, infection, or pain
- Radiation exposure: Relevant to repeated LDCT and CT colonography, though benefit outweighs harm in selected high-risk groups
USMLE Step 2 CK Exam Tips
- 1Screening is for asymptomatic patients. A breast mass, rectal bleeding, or hemoptysis is NOT screening — it is diagnostic evaluation
- 2Pap smear starts at age 21, not at first intercourse
- 3Age 30-65 cervical screening: cytology q3y, hrHPV q5y, or cotesting q5y are all acceptable
- 4Positive FIT or stool DNA-FIT requires colonoscopy as the next best step
- 5Lung cancer screening: remember 50-80, 20 pack-years, current smoker or quit within 15 years
- 6PSA screening age 55-69 is shared decision-making; age >=70 is generally no screening
- 7Do not screen for ovarian, pancreatic, or testicular cancer in average-risk asymptomatic adults
- 8A patient with limited life expectancy is less likely to benefit from cancer screening because benefit is delayed and harms are immediate
practicetest your knowledge on cancer screening overviewApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — preventive medicine and beyond.
open q-bank